Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT1 | P54687 | 13/20 | 0.43 |
| ▸ | BCAT2 | O15382 | 11/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7973564 | 0.80 | TDP1 (0.33) | MAPTHTTALDH1A1 | |
| SCHEMBL9423296 | 0.80 | BCAT1 (0.46) | BCAT1BCAT2SMN1; SMN2ALDH1A1 | |
| SCHEMBL9587737 | 0.80 | BCAT1 (0.42) | BCAT1BCAT2MAPTHSD17B10SMN1; SMN2 | |
| SCHEMBL7930382 | 0.79 | BCAT1 (0.42) | BCAT1BCAT2MAPTHSD17B10SMN1; SMN2 | |
| SCHEMBL7930378 | 0.79 | BCAT1 (0.42) | BCAT1BCAT2MAPTHSD17B10SMN1; SMN2 | |
| SCHEMBL9423250 | 0.79 | BCAT1 (0.48) | BCAT1BCAT2SMN1; SMN2ALDH1A1 | |
| SCHEMBL7844546 | 0.79 | BCAT1 (0.41) | BCAT1BCAT2MAPTHSD17B10SMN1; SMN2 | |
| SCHEMBL9274567 | 0.78 | TDP1 (0.50) | BCAT1BCAT2SMN1; SMN2ALDH1A1 | |
| SCHEMBL6557245 | 0.76 | CA12 (0.46) | BCAT1BCAT2MAPTHSD17B10SMN1; SMN2 | |
| SCHEMBL9581685 | 0.76 | BCAT1 (0.46) | BCAT1BCAT2SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010031865-A1 | Substituted 3-phenyluracils | KLINTZ RALF (DE) | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031865-A1 | Substituted 3-phenyluracils | CCR1, CCR6, CCR3 | BCAT1 139/4885BCAT2 599/4885MAPT 4647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.